Different Genetic Roads Lead to the Same Drug Resistance in Candida albicans

The fungus Candida albicans is one of the most common causes of serious fungal infections in humans, and its growing ability to shrug off antifungal drugs has become a pressing public health concern, especially for patients whose immune systems are weakened by cancer therapy, transplantation, or intensive care. Two of the most important drugs deployed against this organism are fluconazole, an azole that blocks the synthesis of ergosterol, the essential fungal membrane sterol, and caspofungin, an echinocandin that inhibits the enzyme complex that builds beta-glucan, a structural component of the fungal cell wall. When resistance to these agents emerges in the clinic, clinicians are often left with few alternatives, which makes understanding how resistance actually evolves a question of direct medical consequence.

A central puzzle in resistance biology is whether different fungal isolates traveling toward the same resistant phenotype take the same genetic road or different ones. If resistance usually arises through a shared, predictable set of mutations, then diagnostic assays targeting those mutations could catch resistant strains early, and drug development could focus on countering a small number of mechanisms. If, however, resistance can be assembled through many alternative mutational routes, surveillance becomes far harder, because each new resistant isolate may carry a unique genomic signature. A new study published in PLOS One by Mounzer Abbas, Nour Fattouh, Christy Chedraoui, Setrida El Hachem, Tsolaire Sourenian, Ibrahim Bitar, and Roy A. Khalaf set out to answer exactly this question for C. albicans, asking whether antifungal resistance follows convergent or divergent adaptive pathways at the genetic level.

The team’s experimental design was deliberately controlled. They generated six laboratory-induced fluconazole-resistant isolates and six caspofungin-resistant isolates and then subjected all twelve to whole-genome sequencing, paired with a battery of phenotypic tests measuring traits tied to pathogenicity, including ergosterol content, efflux pump activity, chitin levels, and biofilm formation. By evolving resistance in the laboratory under defined conditions, the researchers could compare resistant isolates against their susceptible progenitors and attribute specific genomic changes to the resistance process itself, rather than to the heterogeneous backgrounds of clinical strains collected from different patients.

The fluconazole-resistant isolates told a story of remarkable phenotypic convergence. Every one of the six showed increased ergosterol production, a classic response to azole pressure, because the fungus compensates for the partial inhibition of its ergosterol biosynthesis pathway by pushing the pathway harder. Every one also displayed elevated activity of ATP-binding cassette transporter efflux pumps, the molecular pumps that actively expel fluconazole from the cell before it can reach its target. In other words, at the level of physiology, all six isolates had arrived at essentially the same resistant state, combining target-pathway compensation with active drug export.

When the researchers looked at the underlying DNA sequences, however, the picture became more complicated. Certain mutations recurred across all the fluconazole-resistant isolates, including variants in ERG24, a gene encoding an enzyme in the ergosterol biosynthesis pathway, and a specific substitution, SOD6 S225P, in a superoxide dismutase gene that appears in every resistant isolate. These recurrent changes suggest genuine convergent evolution, with the same amino acid substitutions arising independently in separate lineages because they confer a selective advantage under azole stress. Yet other mutations, such as ERG11 T128K in the direct target of fluconazole, appeared in some isolates but not others, indicating that the resistance program is assembled from a mixture of shared core mutations and isolate-specific accessory changes.

The caspofungin-resistant isolates presented an equally instructive contrast. All six shared a common resistance strategy centered on the cell wall, but the genetic implementation differed from isolate to isolate. Each carried mutations in CHS3, the gene encoding chitin synthase 3, the enzyme responsible for the bulk of chitin synthesis in C. albicans. Because caspofungin blocks beta-glucan synthesis, fungi can compensate by reinforcing their walls with extra chitin, and elevated chitin is a well-established mechanism of echinocandin tolerance. Strikingly, although every resistant isolate increased its chitin content, the magnitude of that increase varied among isolates, tracking the diversity of CHS3 mutations each had acquired. A shared adaptive strategy, chitin reinforcement, was thus implemented through distinct genetic variants with quantitatively different outcomes.

Beyond point mutations, the sequencing analysis, performed with the Yeast Mapping Analysis Pipeline, or YMAP, revealed large-scale chromosomal rearrangements in the resistant isolates. These structural changes, which can include aneuploidy and segmental duplications, add an important dimension to the resistance story because they can amplify the dosage of resistance-conferring genes or alter the copy number of entire chromosomes carrying drug targets. The finding underscores that resistance evolution in C. albicans is not simply a matter of accumulating single-nucleotide changes; genome architecture itself is a mutable substrate, and rearrangements can contribute materially to the acquisition of the resistant phenotype.

Perhaps the most biologically intriguing result concerns what resistance costs. Many of the resistant isolates, for both drugs, showed decreased biofilm formation and reduced virulence-associated characteristics compared with their susceptible counterparts. Biofilms, the surface-attached microbial communities that are particularly problematic on catheters and other medical devices, are energetically expensive structures, and the same cellular remodeling that confers drug resistance appears to impose fitness trade-offs on other traits. This pattern suggests that resistance and virulence are not independently adjustable dials; rather, the evolutionary pressure to survive drug exposure can force the fungus to sacrifice aspects of its pathogenic arsenal, a phenomenon with potential implications for how resistant infections behave in patients.

Taken together, the study delivers a nuanced verdict on the convergence question: convergent phenotypes, divergent genetics. The resistant isolates converged on shared physiological strategies, ergosterol elevation and efflux for fluconazole, chitin reinforcement for caspofungin, and even on some recurrent point mutations, but the full set of genomic changes underlying each resistant phenotype was largely isolate-specific, and chromosomal rearrangements added further heterogeneity. For clinicians and epidemiologists, this means that sequencing a single canonical mutation will not reliably identify all resistant strains, and that resistance surveillance must contend with a shifting mosaic of genetic mechanisms. For drug developers, the fitness trade-offs observed here hint that combination strategies targeting both resistance mechanisms and virulence pathways could exploit the costs that resistance imposes.

The work also highlights the value of laboratory evolution experiments as a complement to clinical genomics. By observing resistance as it emerges under controlled conditions, researchers can distinguish cause from correlation, identify recurrent mutations that represent genuine adaptive solutions, and measure the phenotypic consequences of specific genetic changes. As antifungal resistance continues to spread globally and the pipeline of new antifungal agents remains thin, studies of this kind provide an essential map of the evolutionary landscape that future drugs and diagnostics will need to navigate, one in which the same destination can be reached by many different roads.

Subject of Research: Genetic mechanisms of fluconazole and caspofungin resistance evolution in Candida albicans

Article Title: Diverse genetic pathways drive convergent fluconazole and caspofungin resistance phenotypes in Candida albicans

Article References: Abbas, M., Fattouh, N., Chedraoui, C., El Hachem, S., Sourenian, T., Bitar, I., & Khalaf, R. A. (2026). Diverse genetic pathways drive convergent fluconazole and caspofungin resistance phenotypes in Candida albicans. PLOS One, 21(10), e0360234. https://doi.org/10.1371/journal.pone.0360234

Image Credits: AI Generated

DOI: 10.1371/journal.pone.0360234

Keywords: Candida albicans, antifungal resistance, fluconazole, caspofungin, whole-genome sequencing, ergosterol, efflux pumps, chitin, biofilm, chromosomal rearrangements, evolutionary convergence, virulence trade-offs